Smoking and immunotherapy efficacy in lung cancer by PDL1 subgroups: An individual participant data meta-analysis of atezolizumab clinical trials: Smoking and immunotherapy efficacy in lung cancer

Research output: Contribution to journalLetterpeer-review

Abstract

Immune checkpoint inhibitors (ICIs) are now a cornerstone of advanced non-small cell lung cancer (NSCLC) treatment. However, heterogeneity in ICI benefit is significant, and it is increasingly apparent that resistance is likely multifactorial. As cigarette smoking is associated with increased tumour mutation burden (TMB) [1,2], it is possible that ‘never smokers’ could obtain less ICI benefit. Recent study-level meta-analyses report that never smokers may obtain less effect from ICIs than previous/current smokers [3,4], while small cohort studies report prognosis may be poorer in never smokers compared to previous/current smokers [1,2]. However, these studies (1) used small cohorts, (2) failed to recognise previous and current smokers have different TMBs, and (3) have not reported according to PDL1 expression.
Original languageEnglish
Pages (from-to)279-281
Number of pages3
JournalEuropean Journal of Cancer
Volume160
DOIs
Publication statusPublished - Jan 2022

Keywords

  • Atezolizumab
  • Non-small cell lung cancer
  • Smoking

Fingerprint

Dive into the research topics of 'Smoking and immunotherapy efficacy in lung cancer by PDL1 subgroups: An individual participant data meta-analysis of atezolizumab clinical trials: Smoking and immunotherapy efficacy in lung cancer'. Together they form a unique fingerprint.

Cite this